Supplementary Figure 1

A

![Graph showing latency vs. trials with error bars and significant differences indicated by asterisks.](Image)

B

**PFC - Phospho ERK levels during consolidation (after acquisition)**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>60 min</th>
<th>120 min</th>
<th>240 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>pERK 1/2</td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
</tr>
<tr>
<td>ERK 1/2</td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
<td><img src="Image" alt="Image" /></td>
</tr>
</tbody>
</table>

Consolidation phase:

- 0 min
- 60 min
- 120 min
- 240 min

- minutes after last trial
Supplementary Figure 3

A

B
Vehicle
Vehicle + inhibitor

mPFC

C
FR2

Number of pERK ir. Neurons in mPFC

Control Trained
u0126 injected

Cell number per field

Number of pERK ir. Neurons in FR2

Control Trained
u0126 injected

Cell number per field